Invention Grant
- Patent Title: Deuterated rigosertib
- Patent Title (中): 氘代极限
-
Application No.: US14395795Application Date: 2013-04-19
-
Publication No.: US09249093B2Publication Date: 2016-02-02
- Inventor: Roger D. Tung
- Applicant: Concert Pharmaceuticals, Inc.
- Applicant Address: US MA Lexington
- Assignee: Concert Pharmaceuticals, Inc.
- Current Assignee: Concert Pharmaceuticals, Inc.
- Current Assignee Address: US MA Lexington
- Agency: Hamilton, Brook, Smith & Reynolds, P.C.
- International Application: PCT/US2013/037426 WO 20130419
- International Announcement: WO2013/159026 WO 20131024
- Main IPC: A01N41/10
- IPC: A01N41/10 ; A61K31/10 ; C07C317/28 ; A61K31/519 ; A61K31/444 ; A61K31/4439 ; A61K31/136 ; A61K31/18 ; A61K31/197 ; A61K31/255 ; A61K45/06
Abstract:
This invention relates to novel substituted styryl benzylsulfones that are multikinase inhibitors and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an agent that inhibits kinases, such as phosphatidylinositol 3-kinase (PI3-K) and polo-like kinase (PLK-1).
Public/Granted literature
- US20150094276A1 Deuterated Rigosertib Public/Granted day:2015-04-02
Information query
